AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of 187.40 billion. The enterprise value is 207.59 billion.

Market Cap	187.40B
Enterprise Value	207.59B

Important Dates

The next estimated earnings date is Thursday, July 25, 2024.

Earnings Date	Jul 25, 2024
Ex-Dividend Date	Feb 22, 2024

Share Statistics

AstraZeneca has 1.55 billion shares outstanding.

Shares Outstanding	1.55B
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.06%
Owned by Insiders (%)	0.04%
Owned by Institutions (%)	50.00%
Float	1.54B

Valuation Ratios

The trailing PE ratio is 37.77 and the forward PE ratio is 16.42. AstraZeneca's PEG ratio is 0.89.

PE Ratio	37.77
Forward PE	16.42
PS Ratio	4.98
PB Ratio	6.33
P/FCF Ratio	40.96
PEG Ratio	0.89

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.93, with an EV/FCF ratio of 45.54.

EV / Earnings	41.61
EV / Sales	5.53
EV / EBITDA	19.93
EV / EBIT	30.87
EV / FCF	45.54

Financial Position

The company has a current ratio of 0.89, with a Debt / Equity ratio of 0.92.

Current Ratio	0.89
Quick Ratio	0.66
Debt / Equity	0.92
Debt / EBITDA	2.61
Debt / FCF	5.97
Interest Coverage	5.16

Financial Efficiency

Return on equity (ROE) is 16.91% and return on invested capital (ROIC) is 10.37%.

Return on Equity (ROE)	16.91%
Return on Assets (ROA)	6.19%
Return on Capital (ROIC)	10.37%
Revenue Per Employee	417,289
Profits Per Employee	55,488
Employee Count	89,900
Asset Turnover	0.48
Inventory Turnover	2.57

Taxes

In the past 12 months, AstraZeneca has paid 866.73 million in taxes.

Income Tax	866.73M
Effective Tax Rate	14.80%

Stock Price Statistics

The stock price has increased by +19.10% in the last 52 weeks. The beta is 0.17, so AstraZeneca's price volatility has been lower than the market average.

Beta (5Y)	0.17
52-Week Price Change	+19.10%
50-Day Moving Average	12,232.12
200-Day Moving Average	10,817.53
Relative Strength Index (RSI)	40.27
Average Volume (20 Days)	1,988,908

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of 37.51 billion and earned 4.99 billion in profits. Earnings per share was 3.20.

Revenue	37.51B
Gross Profit	30.75B
Operating Income	6.90B
Pretax Income	5.86B
Net Income	4.99B
EBITDA	10.42B
EBIT	6.73B
Earnings Per Share (EPS)	3.20

Full Income Statement

Balance Sheet

The company has 6.32 billion in cash and 27.22 billion in debt, giving a net cash position of -20.90 billion or -13.48 per share.

Cash & Cash Equivalents	6.32B
Total Debt	27.22B
Net Cash	-20.90B
Net Cash Per Share	-13.48
Equity (Book Value)	29.50B
Book Value Per Share	19.03
Working Capital	-2.61B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 7.64 billion and capital expenditures -3.08 billion, giving a free cash flow of 4.56 billion.

Operating Cash Flow	7.64B
Capital Expenditures	-3.08B
Free Cash Flow	4.56B
FCF Per Share	2.92

Full Cash Flow Statement

Margins

Gross margin is 81.98%, with operating and profit margins of 18.40% and 13.30%.

Gross Margin	81.98%
Operating Margin	18.40%
Pretax Margin	15.62%
Profit Margin	13.30%
EBITDA Margin	27.77%
EBIT Margin	17.93%
FCF Margin	12.15%

Dividends & Yields

This stock pays an annual dividend of 2.28, which amounts to a dividend yield of 1.89%.

Dividend Per Share	2.28
Dividend Yield	1.89%
Dividend Growth (YoY)	-4.77%
Years of Dividend Growth	2
Payout Ratio	71.13%
Buyback Yield	n/a
Shareholder Yield	0.02%
Earnings Yield	2.67%
FCF Yield	2.44%

Dividend Details

Analyst Forecast

Price Target	13,025.00
Price Target Difference	7.75%
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a